US 12,357,586 · Application 17/585,415 · Granted Jul 15, 2025
US 12,357,586
Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy
Estimated expiration
January 3, 2032
5y 96d remaining
- Could not fetch continuity data for application PCTGB2012050002: Resource not found (404)
Earliest effective filing
Jan 3, 2012
+ 20 years
Jan 3, 2032
PTA +0d
Jan 3, 2032
No TD
—
Final
Jan 3, 2032
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- January 26, 2022
- Earliest effective filing
- January 3, 2012
- Issue date
- July 15, 2025
- PTA
- 0 days
- Base expiry (before PTA)
- January 3, 2032
January 3, 2012 + 20 years = January 3, 2032
- Continuation of application 13/977,766, filed Jul 1, 2013
- National stage entry of application PCTGB2012050002, filed Jan 3, 2012
- National stage entry of application PCTGB2012050002, filed Jan 3, 2012
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 17/585,415 · US 12,357,586
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 12,357,586: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US12357586Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.